Last reviewed · How we verify
Matching placebo to Aliskiren
This is a matching placebo formulation designed to mimic Aliskiren, a direct renin inhibitor that blocks the first step of the renin-angiotensin-aldosterone system.
This is a matching placebo formulation designed to mimic Aliskiren, a direct renin inhibitor that blocks the first step of the renin-angiotensin-aldosterone system. Used for Used as control in clinical trials for hypertension management.
At a glance
| Generic name | Matching placebo to Aliskiren |
|---|---|
| Sponsor | Novartis |
| Drug class | Placebo (matching Aliskiren, a direct renin inhibitor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
As a placebo, this product contains no active pharmaceutical ingredient and serves as a control comparator in clinical trials. Aliskiren itself works by directly inhibiting renin, the enzyme that initiates the cascade of blood pressure regulation. By blocking renin, it prevents the formation of angiotensin II, thereby reducing vasoconstriction and aldosterone secretion.
Approved indications
- Control arm in clinical trials of Aliskiren for hypertension
Common side effects
Key clinical trials
- Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis (PHASE3)
- Aliskiren Study of Safety and Efficacy in Senior Hypertensives (PHASE4)
- Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension (PHASE2)
- Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases) (PHASE3)
- Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure (PHASE3)
- Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes (PHASE4)
- To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy (PHASE2)
- A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Matching placebo to Aliskiren CI brief — competitive landscape report
- Matching placebo to Aliskiren updates RSS · CI watch RSS
- Novartis portfolio CI